The levels of clarithromycin and its 14-hydroxy metabolite in the lung

Clarithromycin is a new macrolide that has a longer half-life than erythromycin and is claimed to reach higher tissue concentrations. We aimed to investigate whether, following oral administration, the drug and its 14-hydroxy metabolite reach levels in lung tissue that are likely to be clinically effective against common respiratory pathogens. Ten patients undergoing diagnostic bronchoscopy received seven doses of clarithromycin, 500 mg b.i.d. orally. Bronchoscopy was performed at a mean time of 4.25 h after the last dose. At bronchoscopy, bronchial biopsies and bronchoalveolar lavage were performed. Clarithromycin and its 14-OH metabolite were measured in serum, bronchial biopsies, epithelial lining fluid (ELF) and alveolar cells. Mean levels of clarithromycin were 4.0 mg.l-1 in serum, 16.8 mg.kg in bronchial biopsies, 20.5 mg.l-1 in ELF and 372.7 mg.l-1 in alveolar cells. The equivalent levels of 14-OH metabolite were 0.7, 2.7, 1.9 and 38.6 mg.l-1, respectively. We conclude that there is considerable concentration of clarithromycin and its 14-OH metabolite in alveolar cells, and to a lesser extent in bronchial tissue and ELF; this implies efficacy against susceptible organisms at these sites.

This article has been cited by other articles:

				S. Kiem and J. J. Schentag Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid Antimicrob. Agents Chemother., January 1, 2008; 52(1): 24 - 36. [Full Text] [PDF]

				F. Traunmuller, M. Zeitlinger, P. Zeleny, M. Muller, and C. Joukhadar Pharmacokinetics of Single- and Multiple-Dose Oral Clarithromycin in Soft Tissues Determined by Microdialysis Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3185 - 3189. [Abstract] [Full Text] [PDF]

				M. H. Gotfried, L. H. Danziger, and K. A. Rodvold Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects J. Antimicrob. Chemother., September 1, 2003; 52(3): 450 - 456. [Abstract] [Full Text] [PDF]

				T. Shimizu, S. Shimizu, R. Hattori, E. C. Gabazza, and Y. Majima In Vivo and In Vitro Effects of Macrolide Antibiotics on Mucus Secretion in Airway Epithelial Cells Am. J. Respir. Crit. Care Med., September 1, 2003; 168(5): 581 - 587. [Abstract] [Full Text] [PDF]

				O. A. Khair, J. M. Andrews, D. Honeybourne, G. Jevons, F. Vacheron, and R. Wise Lung concentrations of telithromycin after oral dosing J. Antimicrob. Chemother., June 1, 2001; 47(6): 837 - 840. [Abstract] [Full Text] [PDF]

				T. Ichiyama, M. Nishikawa, T. Yoshitomi, S. Hasegawa, T. Matsubara, T. Hayashi, and S. Furukawa Clarithromycin Inhibits NF-{kappa}B Activation in Human Peripheral Blood Mononuclear Cells and Pulmonary Epithelial Cells Antimicrob. Agents Chemother., January 1, 2001; 45(1): 44 - 47. [Abstract] [Full Text]

				K. L. Bergman, K. M. Olsen, T. E. Peddicord, P. D. Fey, and M. E. Rupp Antimicrobial Activities and Postantibiotic Effects of Clarithromycin, 14-Hydroxy-Clarithromycin, and Azithromycin in Epithelial Cell Lining Fluid against Clinical Isolates of Haemophilus influenzae and Streptococcus pneumoniae Antimicrob. Agents Chemother., May 1, 1999; 43(5): 1291 - 1293. [Abstract] [Full Text]